Vera Therapeutics, Inc. (NASDAQ:VERA) Given Average Rating of “Buy” by Brokerages

Vera Therapeutics, Inc. (NASDAQ:VERA) has been assigned a consensus rating of “Buy” from the nine ratings firms that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a hold recommendation, six have given a buy recommendation and two have issued a strong buy recommendation on the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $57.88.

A number of analysts recently commented on the company. Evercore ISI raised Vera Therapeutics to a “strong-buy” rating in a research report on Monday, September 16th. Scotiabank assumed coverage on Vera Therapeutics in a report on Wednesday, October 16th. They set a “sector outperform” rating and a $60.00 price objective on the stock. JPMorgan Chase & Co. upped their target price on shares of Vera Therapeutics from $72.00 to $75.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 5th. Cantor Fitzgerald restated an “overweight” rating and issued a $107.00 price objective on shares of Vera Therapeutics in a research report on Tuesday, October 1st. Finally, Wedbush lifted their price target on Vera Therapeutics from $30.00 to $38.00 and gave the company a “neutral” rating in a research report on Friday.

Insider Buying and Selling

In related news, CEO Marshall Fordyce sold 14,471 shares of Vera Therapeutics stock in a transaction dated Wednesday, August 21st. The stock was sold at an average price of $39.76, for a total value of $575,366.96. Following the completion of the transaction, the chief executive officer now owns 322,667 shares in the company, valued at $12,829,239.92. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In related news, Director Beth C. Seidenberg sold 15,000 shares of the company’s stock in a transaction that occurred on Monday, October 28th. The shares were sold at an average price of $48.03, for a total transaction of $720,450.00. Following the sale, the director now directly owns 131,553 shares of the company’s stock, valued at $6,318,490.59. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Marshall Fordyce sold 14,471 shares of the company’s stock in a transaction that occurred on Wednesday, August 21st. The stock was sold at an average price of $39.76, for a total transaction of $575,366.96. Following the sale, the chief executive officer now owns 322,667 shares in the company, valued at $12,829,239.92. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 104,398 shares of company stock worth $4,376,163. 21.70% of the stock is owned by company insiders.

Institutional Trading of Vera Therapeutics

A number of large investors have recently bought and sold shares of VERA. Avoro Capital Advisors LLC acquired a new position in Vera Therapeutics during the first quarter worth about $227,027,000. Price T Rowe Associates Inc. MD acquired a new position in shares of Vera Therapeutics in the first quarter worth about $103,189,000. Samlyn Capital LLC raised its holdings in Vera Therapeutics by 90.8% in the second quarter. Samlyn Capital LLC now owns 1,231,911 shares of the company’s stock valued at $44,571,000 after acquiring an additional 586,410 shares in the last quarter. First Light Asset Management LLC raised its stake in Vera Therapeutics by 130.6% during the second quarter. First Light Asset Management LLC now owns 1,005,723 shares of the company’s stock valued at $36,387,000 after buying an additional 569,590 shares in the last quarter. Finally, Vanguard Group Inc. increased its stake in Vera Therapeutics by 31.5% during the first quarter. Vanguard Group Inc. now owns 2,148,714 shares of the company’s stock valued at $92,653,000 after purchasing an additional 515,106 shares during the last quarter. Institutional investors and hedge funds own 99.21% of the company’s stock.

Vera Therapeutics Stock Performance

Shares of VERA stock opened at $48.67 on Thursday. The company has a fifty day moving average price of $41.75 and a two-hundred day moving average price of $39.23. Vera Therapeutics has a one year low of $11.69 and a one year high of $50.78. The stock has a market cap of $2.67 billion, a P/E ratio of -18.65 and a beta of 1.03. The company has a debt-to-equity ratio of 0.15, a current ratio of 21.43 and a quick ratio of 21.43.

Vera Therapeutics (NASDAQ:VERA) last released its earnings results on Thursday, November 7th. The company reported ($0.85) earnings per share for the quarter, missing the consensus estimate of ($0.64) by ($0.21). As a group, equities analysts predict that Vera Therapeutics will post -2.55 EPS for the current year.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.